Unpulsed DCs

Phase 2Biologic

MMustafa Khasraw, MBChB, MD, FRCP, FRACP

Unpulsed DCs is one of 5 biologic programs targeting GBM. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GBMCompleted

GBMPhase 2

Completed

Competition

Competitive Landscape

4 competitors in GBM

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

3 2

Zejula

GGlaxo Dba Glaxosmithkline

Phase 2

1 3

Varlilumab

NNational Cancer Institute (NCI)

Phase 2

1 4

D2C7-IT

DDarell Bigner

Phase 1

1 5

Unpulsed DCs

MMustafa Khasraw, MBChB, MD, FRCP, FRACP

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

GBM2 trials

DC Migration Study for Newly-Diagnosed GBM

Completed·MMustafa Khasraw, MBChB, MD, FRCP, FRACP·Phase 2·NCT02366728·64 enrolled

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

Active, not recruiting·—·Phase 2·NCT03688178·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Unpulsed DCs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Unpulsed DCs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Unpulsed DCs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mustafa Khasraw, MBChB, MD, FRCP, FRACP company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: MMustafa Khasraw, MBChB, MD, FRCP, FRACP

Unpulsed DCs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

GBM2 trials

References

Drug Info

Quick Facts

Related News